ascorbic-acid and 2-aminomethyl-4-t-butyl-6-iodophenol

The effects of phenolic anti-inflammatory drug, MK-447, on prostaglandin (PG) I2 and thromboxane (TX) A2 biosynthesis by rat dental pulp tissue were evaluated in the presence of 10 mM mannitol (MA) or 1 mM ascorbic acid with 0.3 mM Fe2+ (A + F). Although MK-447 alone at 1 and 10 microM had no significant effects, MK-447 at 100 microM stimulated both PGI2 and TXA2 biosynthesis, and suppressed the lipid peroxidation in the pulp tissue as estimated by thiobarbituric acid method. MA also reduced the lipid peroxidation, but had no effect on PG and TX production. However, in the presence of MA, the stimulatory effect of MK-447 was potentiated, and the significant effects were observed at concentrations higher than 1 microM. In contrast, A + F remarkably stimulated the lipid peroxidation, and inhibited both PG and TX biosynthesis. In the presence of A + F, MK-447 showed no stimulatory effect, and contrary, at 100 microM inhibited PG and TX production. These results suggest that the cellular levels of lipid peroxidation exert a significant influence on the effects of phenolic anti-inflammatory drugs like MK-447 on PG biosynthesis. The possible mechanism of action for such drugs has been discussed in view of the significance of lipid peroxidation in inflammatory condition.

Topics: Animals; Anti-Inflammatory Agents; Ascorbic Acid; Butylated Hydroxytoluene; Dental Pulp; Ferrous Compounds; In Vitro Techniques; Lipid Peroxides; Male; Mannitol; Prostaglandins; Rats; Rats, Inbred Strains; Thromboxane A2

Carcinogens which cause cancers in tissues distal to their entry are thought to require metabolic activation before covalent binding to macromolecules. The hydroperoxidase component of prostaglandin H synthase (PHS) activates certain carcinogens and a model describing this process is presented. The procarcinogen benzidine was used to identify sites at which microsomal PHS-catalyzed binding might be inhibited by pharmacologic agents. Activation of benzidine was determined by assessing free radical cation formation and covalent binding to protein. Reduction of benzidine diimine to diamine was also assessed. This study provides the first demonstration of inhibition of PHS-activated benzidine binding by propylthiouracil, methimazole, MK447, vitamin C and phenidone. The agents tested identified the following sites at which PHS-catalyzed binding of benzidine can be prevented: 1) inhibition of generation of the peroxide cosubstrate for benzidine oxidation; 2) inhibition of prostaglandin hydroperoxidase; 3) reduction of oxidized intermediate(s) to the parent compound; and 4) conjugation of the activated intermediate(s). This study provides a basis for further investigations of the pharmacologic intervention of chemical carcinogenesis.

Topics: Animals; Arachidonic Acid; Arachidonic Acids; Ascorbic Acid; Benzidines; Binding Sites; Butylated Hydroxytoluene; Carcinogens; Dose-Response Relationship, Drug; Drug Interactions; Indomethacin; Male; Methimazole; Microsomes; Models, Chemical; Peroxidases; Propylthiouracil; Prostaglandin Endoperoxides; Prostaglandin-Endoperoxide Synthases; Prostaglandins H; Protein Binding; Pyrazoles; Rabbits; Stimulation, Chemical